Evidence map›Paper›PMID 22858914›Full record

ReviewMinerva cardioangiologica2012

Gene and cell therapies for the failing heart to prevent sudden arrhythmic death.

A A Sovari, S C Dudley

Abstract readReview
In one paragraph

Review in Minerva cardioangiologica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

A A SovariUniversity of Illinois at Chicago, Chicago, IL, USA.
S C Dudley
University of Illinois Chicago · US

Funding

Vascular specific ACE expression and atherosclerosisP01HL058000 · NHLBI · VANDERBILT UNIVERSITY · PI DIKALOV, SERGEY · 1998 to 2013
$20.7M
Training in Mechanisms of Cardiovascular DiseasesT32HL072742 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI TOBACMAN, LARRY S · 2003 to 2013
$3.7M
Na+ channel mRNA splicing in heart failureR01HL104025 · NHLBI · UNIVERSITY OF MINNESOTA · PI DUDLEY, SAMUEL C · 2011 to 2019
$3.3M
Metabolic Regulation of Sodium ChannelsR01HL106592 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DUDLEY, SAMUEL C · 2011 to 2014
$1.6M
American Heart Association-American Stroke Association 10POST4450037NHLBI NIH HHS P01 HL058000NHLBI NIH HHS R01 HL104025NHLBI NIH HHS R01 HL106592NHLBI NIH HHS T32 HL072742
6 · The paper itself

Abstract

Current therapies for treatment and prevention of sudden cardiac death have certain limitations, and a search for new therapeutic approaches is desirable to reduce the burden of sudden arrhythmic death. Gene therapy and stem cell therapy have been investigated as new, valuable tools in treating cardiac diseases such as arrhythmias. In this review, the basics of each modality, important related experimental and clinical studies, and potential advantages and limitations of these treatments will be discussed. The future success of gene and cell therapy to become practical clinical tools greatly depends on our understanding of the mechanisms of ventricular arrhythmia and the mechanisms of action of gene and cell therapy.

Indexed as

Genetic TherapyStem Cell TransplantationArrhythmias, CardiacDeath, Sudden, CardiacHeart FailureHumansTreatment Outcome

Identifiers

PMID22858914
PMCPMC3655203
OpenAlexW131526220

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.